How Should an Incidental Fatty Liver Finding Be Evaluated?

Answer in brief: An incidental report of hepatic steatosis should trigger assessment for metabolic risk, alcohol exposure and other causes of steatosis, followed by fibrosis risk stratification rather than reflexive liver biopsy. FIB-4 is an appropriate first-line tool in most adults; patients with elevated or indeterminate results should undergo VCTE, ELF or another validated second-line test. The key prognostic question is fibrosis stage, not the amount of fat seen on imaging.

Key clinical points

Confirm that the patient has cardiometabolic risk factors consistent with MASLD.
Quantify alcohol exposure rather than assuming “social” use is insignificant.
Calculate FIB-4 from stable laboratory values.
Escalate to elastography/ELF when fibrosis risk is not clearly low.

First determine the cause

Steatosis can occur with MASLD, alcohol, medications, malnutrition, rapid weight loss and less common metabolic conditions. MASLD requires hepatic steatosis plus at least one cardiometabolic risk factor in the absence of another dominant explanation.

Fibrosis is the prognostic pivot

Routine ultrasound or CT can identify fat but does not accurately stage inflammation or fibrosis. FIB-4 is therefore a practical initial risk assessment. Low-risk patients can often be managed with metabolic intervention and periodic reassessment; higher-risk patients move to VCTE or ELF and, when appropriate, hepatology referral.

Laboratory evaluation

Review aminotransferases, alkaline phosphatase, bilirubin, albumin, CBC/platelets and metabolic measures. Depending on history, evaluate viral hepatitis and other chronic liver diseases. Normal aminotransferases do not exclude significant fibrosis.

Management

Weight loss, physical activity and treatment of diabetes, dyslipidemia and hypertension are central. Statins should not be withheld solely because MASLD is present. Patients with F2–F3 MASH may now be candidates for disease-specific therapy after appropriate staging.

Practical approach

1. Define the liver-disease phenotype and metabolic/alcohol/medication context.

2. Use FIB-4 as first-line fibrosis triage when appropriate.

3. Escalate to VCTE/ELF or other testing when risk is indeterminate or high.

4. Refer or biopsy when noninvasive tests conflict, advanced disease is likely or diagnosis remains uncertain.

Common errors to avoid

Treating FIB-4 or elastography as a stand-alone diagnosis.
Interpreting noninvasive fibrosis tests during acute illness without context.

Trainee takeaway

An incidental report of hepatic steatosis should trigger assessment for metabolic risk, alcohol exposure and other causes of steatosis, followed by fibrosis risk stratification rather than reflexive liver biopsy. The examination question is usually less about memorizing one cutoff than recognizing which finding changes the next clinical decision.

Relevant free books by Dr. Alan B. R. Thomson

Thomson ABR. Mastering the Boards and Clinical Examinations in Internal Medicine: Hepatology. CAPstone Academic Publishers; 2016. ISBN 978-1519751195.
Thomson ABR. Guideline-Based Management in Hepatology. CAPstone Academic Publishers; 2015. ISBN 978-1502928078.

Free downloads: https://giandhepatology.com/free-medical-books-on-gastroenterology-and-hepatology

Frequently asked questions

Does fatty liver on ultrasound mean the patient has MASH?

No. Imaging shows steatosis but cannot reliably distinguish simple steatosis from steatohepatitis.

When is biopsy needed?

Usually when diagnosis remains uncertain, noninvasive tests conflict, or histology would change management.

References

1. Thomson ABR. Mastering the Boards and Clinical Examinations in Internal Medicine: Hepatology. CAPstone Academic Publishers; 2016. ISBN 978-1519751195.

2. Thomson ABR. Guideline-Based Management in Hepatology. CAPstone Academic Publishers; 2015. ISBN 978-1502928078.

3. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797-1835. doi:10.1097/HEP.0000000000000323.

4. AASLD. Resmetirom Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease: October 2024 Updates to AASLD Practice Guidance.

5. AASLD. Semaglutide Therapy for Metabolic Dysfunction-Associated Steatohepatitis: November 2025 Updates to AASLD Practice Guidance.

Editorial note: This educational article synthesizes Dr. Thomson’s teaching framework with current society guidance. Recommendations should be checked against the latest guideline, local formulary, regulatory labeling and the individual clinical context before patient-specific use.